One of the questions I am most asked at the charity is when we can ditch warfarin and go onto the new oral anticoagulants such as Dabigatran.
Dabigatran has been licenced for AF in the UK but has not been trialled for APS patients so is deemed as unsafe for now.
I'm pleased to announce that the APS Trial Committee headed by Professor Hannah Cohen, has been awarded £250K to begin a two centre trial - at Tommies and UCL. The initial research will take a year but it's envisaged (depending on grant funding of course) that the whole project will take three years.